WO2011049625A1 - Method for aflatoxin screening of products - Google Patents

Method for aflatoxin screening of products Download PDF

Info

Publication number
WO2011049625A1
WO2011049625A1 PCT/US2010/002804 US2010002804W WO2011049625A1 WO 2011049625 A1 WO2011049625 A1 WO 2011049625A1 US 2010002804 W US2010002804 W US 2010002804W WO 2011049625 A1 WO2011049625 A1 WO 2011049625A1
Authority
WO
WIPO (PCT)
Prior art keywords
aflatoxin
composite
bins
sample
bin
Prior art date
Application number
PCT/US2010/002804
Other languages
French (fr)
Inventor
Mansour Samadpour
Original Assignee
Mansour Samadpour
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mansour Samadpour filed Critical Mansour Samadpour
Publication of WO2011049625A1 publication Critical patent/WO2011049625A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi

Definitions

  • the present invention relates to a method for avoiding waste of food and other products related to a positive test for the presence of aflatoxin and similar toxins.
  • microbial toxins such as aflatoxin and other mycotoxins
  • pistachio and almond aflatoxin testing relies on collecting 5-10 kg of sample from 20-22 bins/bags of products, each containing about 2000 pounds of the product. The sample is then homogenized/blended and a small portion (150 grams) is subjected to ethanol extraction followed by cleanup and detection. Under the prior art, if the sample tests positive, all 20-22 bins/bags are typically destroyed, with economic loss to the producers.
  • each bin/bag is sampled individually, each sample is
  • a new composite is formed from bags/bins that have below acceptable limit levels of the toxin, and tested to issue a certificate of analysis.
  • bags that have a mean average of toxin level falling below the acceptable limit for the lot can be used to form a composite and an additional test performed to verify the level of toxin in this composite.
  • the final composite may not need to be formed and tested. Instead an arithmetic mean of the bags that have suitable levels of toxins can be calculated to estimate a final level and issue a certificate based on individual bag/bin/test results.
  • aflatoxin is used as an exemplary toxin which may be deal with using the disclosed process.
  • the process may just as well be used with other mycotoxins or other forms of contamination as needs dictate.
  • Fig. 1 is a flow diagram of the method disclosed herein.
  • Fig. 1 shows test lot 1, which is a collection of bins 2 containing product 3, which may be food product such as nuts, including pistachios or almonds.
  • Sampling device 4 is used to take a sample of product from each bin, each sample is homogenized by blending device 5, and placed in individual sample containers 6. A portion of the contents of each container 6 is then taken and placed in composite sample container 7. The contents of 7 are well mixed and subjected to aflatoxin testing process 8. Meanwhile, each container 6 and its remaining contents are stored in holding area 9. If the results of testing process 8 show aflatoxin at acceptable levels, then the entire test lot of bins is released for delivery to the customer.
  • results of testing process 8 show aflatoxin above acceptable limits in the test lot, then individual containers in holding area 9, each containing sample from a single bin 2, are tested to determine the level of aflatoxin present in individual bins 2. If a particular bin 2 is thus identified to have an above-acceptable level of aflatoxin, that bin is excluded from shipment.
  • the remaining bins may be assembled into a lot that may be released to the customer, and a certificate of compliance with aflatoxin standards for the lot may be based upon the mathematically averaged results of the previous individual tests or upon additional testing of a composite formed from taking samples from such of the individual samples 6 as tested at acceptable levels.

Abstract

A method for screening a lot of product comprising multiple, individual bags or bins wherein a samples taken from each bag or bin are formed into a composite, which composite is tested for toxin or other contamination. If the test shows positive, the samples are then tested individually to determine which bag or bin is contaminated, thus permitting non-contaminated bags or bins to be released.

Description

METHOD FOR AFLATOXIN SCREENING OF PRODUCTS
The present invention relates to a method for avoiding waste of food and other products related to a positive test for the presence of aflatoxin and similar toxins.
Currently, testing for microbial toxins such as aflatoxin and other mycotoxins is conducted in a manner that results in rejection of the entire lot of the product. For instance pistachio and almond aflatoxin testing relies on collecting 5-10 kg of sample from 20-22 bins/bags of products, each containing about 2000 pounds of the product. The sample is then homogenized/blended and a small portion (150 grams) is subjected to ethanol extraction followed by cleanup and detection. Under the prior art, if the sample tests positive, all 20-22 bins/bags are typically destroyed, with economic loss to the producers.
In the current invention each bin/bag is sampled individually, each sample is
blended/homogenized individually, and a composite consisting of preferably equal volumes taken from each sample homogenate/blend is formed and subjected to the detection protocol. If the result is acceptable, then the entire group of bins/bags is accepted. However, if the levels of the toxin are higher than the accepted standards, then each bin/bag homogenate is tested separately, and any bin/bag for
l which the corresponding homogenate has a higher than acceptable limit is then excluded. A new composite is formed from bags/bins that have below acceptable limit levels of the toxin, and tested to issue a certificate of analysis. Alternatively, bags that have a mean average of toxin level falling below the acceptable limit for the lot can be used to form a composite and an additional test performed to verify the level of toxin in this composite. Alternatively the final composite may not need to be formed and tested. Instead an arithmetic mean of the bags that have suitable levels of toxins can be calculated to estimate a final level and issue a certificate based on individual bag/bin/test results.
In the following, "aflatoxin" is used as an exemplary toxin which may be deal with using the disclosed process. However, the process may just as well be used with other mycotoxins or other forms of contamination as needs dictate.
Brief Description of the Drawing
Fig. 1 is a flow diagram of the method disclosed herein.
Detailed Description
Fig. 1 shows test lot 1, which is a collection of bins 2 containing product 3, which may be food product such as nuts, including pistachios or almonds. Sampling device 4 is used to take a sample of product from each bin, each sample is homogenized by blending device 5, and placed in individual sample containers 6. A portion of the contents of each container 6 is then taken and placed in composite sample container 7. The contents of 7 are well mixed and subjected to aflatoxin testing process 8. Meanwhile, each container 6 and its remaining contents are stored in holding area 9. If the results of testing process 8 show aflatoxin at acceptable levels, then the entire test lot of bins is released for delivery to the customer. If results of testing process 8 show aflatoxin above acceptable limits in the test lot, then individual containers in holding area 9, each containing sample from a single bin 2, are tested to determine the level of aflatoxin present in individual bins 2. If a particular bin 2 is thus identified to have an above-acceptable level of aflatoxin, that bin is excluded from shipment.
Meanwhile, the remaining bins may be assembled into a lot that may be released to the customer, and a certificate of compliance with aflatoxin standards for the lot may be based upon the mathematically averaged results of the previous individual tests or upon additional testing of a composite formed from taking samples from such of the individual samples 6 as tested at acceptable levels.

Claims

Claim I claim:
1. A method for screening a test lot of product, which lot is comprised of a plurality containers such as bins or bags or the like, which method comprises the steps of:
a) taking at least one sample from each container;
b) taking a portion of each sample and combining these portions into a composite;
c) testing said composite for contamination;
d) in the event the testing of step c) indicates contamination, retesting the samples taken in step a) to determine the level of contamination in each container.
PCT/US2010/002804 2009-10-20 2010-10-19 Method for aflatoxin screening of products WO2011049625A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27955709P 2009-10-20 2009-10-20
US61/279,557 2009-10-20

Publications (1)

Publication Number Publication Date
WO2011049625A1 true WO2011049625A1 (en) 2011-04-28

Family

ID=43900599

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/002804 WO2011049625A1 (en) 2009-10-20 2010-10-19 Method for aflatoxin screening of products

Country Status (1)

Country Link
WO (1) WO2011049625A1 (en)

Citations (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3969287A (en) 1972-12-08 1976-07-13 Boehringer Mannheim Gmbh Carrier-bound protein prepared by reacting the protein with an acylating or alkylating compound having a carrier-bonding group and reacting the product with a carrier
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4247642A (en) 1977-02-17 1981-01-27 Sumitomo Chemical Company, Limited Enzyme immobilization with pullulan gel
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4301144A (en) 1979-07-11 1981-11-17 Ajinomoto Company, Incorporated Blood substitute containing modified hemoglobin
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4670417A (en) 1985-06-19 1987-06-02 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
WO1990005719A1 (en) 1988-11-23 1990-05-31 British Bio-Technology Limited Hydroxamic acid based collagenase inhibitors
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
WO1993021259A1 (en) 1992-04-14 1993-10-28 Cornell Research Foundation Inc. Dendritic based macromolecules and method of production
EP0606046A1 (en) 1993-01-06 1994-07-13 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids
JPH08175990A (en) 1994-12-19 1996-07-09 Mitsubishi Chem Corp Pi3 kinase-inhibiting agent and its production
JPH08176070A (en) 1994-12-19 1996-07-09 Mitsubishi Chem Corp Didepside derivative and pi3 kinase inhibitor
WO1996027583A1 (en) 1995-03-08 1996-09-12 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
WO1996033172A1 (en) 1995-04-20 1996-10-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
WO1997015658A1 (en) 1995-10-26 1997-05-01 Ludwig Institute For Cancer Research Wortmannin phosphoinositide 3-kinase interaction site
EP0780386A1 (en) 1995-12-20 1997-06-25 F. Hoffmann-La Roche Ag Matrix metalloprotease inhibitors
US5646176A (en) 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
WO1998003516A1 (en) 1996-07-18 1998-01-29 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
WO1998007697A1 (en) 1996-08-23 1998-02-26 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
WO1998030566A1 (en) 1997-01-06 1998-07-16 Pfizer Inc. Cyclic sulfone derivatives
WO1998033768A1 (en) 1997-02-03 1998-08-06 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
WO1998034915A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
WO1998034918A1 (en) 1997-02-11 1998-08-13 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
WO1999002514A2 (en) 1997-07-08 1999-01-21 Bristol-Myers Squibb Company Epothilone derivatives
WO1999029667A1 (en) 1997-12-05 1999-06-17 Pfizer Limited Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors
EP0931788A2 (en) 1998-01-27 1999-07-28 Pfizer Limited Metalloprotease inhibitors
WO1999052889A1 (en) 1998-04-10 1999-10-21 Pfizer Products Inc. (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
WO1999052910A1 (en) 1998-04-10 1999-10-21 Pfizer Products Inc. Bicyclic hydroxamic acid derivatives
US6262094B1 (en) 1999-02-22 2001-07-17 Bristol-Myers Squibb Company C-21 modified epothilones
JP2001247477A (en) 2000-03-03 2001-09-11 Teikoku Hormone Mfg Co Ltd Antitumor medicine
WO2001081346A2 (en) 2000-04-25 2001-11-01 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
WO2003035618A2 (en) 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
WO2003034997A2 (en) 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
WO2003037886A2 (en) 2001-10-30 2003-05-08 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
US6608056B1 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd Fused heteroaryl derivatives
WO2004007491A1 (en) 2002-07-10 2004-01-22 Applied Research Systems Ars Holding N.V. Azolidinone-vinyl fused-benzene derivatives
WO2004006916A1 (en) 2002-07-10 2004-01-22 Applied Research Systems Ars Holding Nv Use of compounds for increasing spermatozoa motility
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
US6703414B2 (en) 2001-09-14 2004-03-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Device and method for treating restenosis
US20040053946A1 (en) 2001-01-16 2004-03-18 Lackey Karen Elizabeth Cancer treatment method
EP1417976A1 (en) 2001-07-26 2004-05-12 Santen Pharmaceutical Co., Ltd. Remedy for glaucoma comprising as the active ingredient compound having pi3 kinase inhibitory effect
US20040092561A1 (en) 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
WO2006046031A1 (en) 2004-10-25 2006-05-04 Piramed Limited Pharmaceutical compounds
US20060115824A1 (en) * 2004-04-15 2006-06-01 Institute For Environmental Health, Inc. Trend analysis and statistical process control using multitargeted screening assays
US20060270673A1 (en) 2003-04-24 2006-11-30 Merck & Co., Inc. Inhibitors of akt activity
WO2007042806A1 (en) 2005-10-11 2007-04-19 Ludwig Institute For Cancer Research Pyrimidine derivatives for the treatment of cancer
US20080039459A1 (en) 2006-04-26 2008-02-14 Plramed Limited Phosphoinositide 3-kinase inhibitor compounds and methods of use
US20080076768A1 (en) 2006-04-26 2008-03-27 Piramed Limited Pharmaceutical compounds
WO2008070740A1 (en) 2006-12-07 2008-06-12 F.Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
WO2008073785A2 (en) 2006-12-07 2008-06-19 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and methods of use
US7534584B2 (en) * 2004-08-06 2009-05-19 Institute For Environmental Health, Inc. Modular compositing-multiple lot screening protocols for detection of pathogens, microbial contaminants and/or constituents
WO2009105712A1 (en) 2008-02-22 2009-08-27 Irm Llc Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
WO2009109867A2 (en) 2008-03-04 2009-09-11 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
WO2009111531A1 (en) 2008-03-06 2009-09-11 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2009111547A1 (en) 2008-03-04 2009-09-11 Wyeth 7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
US7589101B2 (en) 2005-08-16 2009-09-15 Irm Llc Compounds and compositions as protein kinase inhibitors
US20090233950A1 (en) 2006-03-02 2009-09-17 Frederic Henri Jung Quinazoline derivatives
US20090234132A1 (en) 2006-05-23 2009-09-17 Novartis Ag 5-phenyl-thiazol-2-yl-urea derivatives and use as pi3 kinase inhibitors
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
WO2009112565A1 (en) 2008-03-13 2009-09-17 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-indazoles
US20090233926A1 (en) 2006-09-14 2009-09-17 Astrazeneca 2-benzimidazolyl-6-morpholino-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
US7592342B2 (en) 2007-05-10 2009-09-22 Smithkline Beecham Corporation Quinoxaline derivatives as PI3 kinase inhibitors
US20090239847A1 (en) 2008-03-19 2009-09-24 Ian Bruce Organic compounds
WO2009117097A1 (en) 2008-03-19 2009-09-24 Chembridge Corporation Novel tyrosine kinase inhibitors
US20090238828A1 (en) 2004-08-14 2009-09-24 Boehringer Ingelheim International Gmbh Combinations for the Treatment of Diseases involving Cell Proliferation
WO2009117482A1 (en) 2008-03-19 2009-09-24 Osi Pharmaceuticals, Inc Mtor inhibitor salt forms
US20090239936A1 (en) 2006-05-15 2009-09-24 Yoshikazu Sugimoto Prophylactic and Therapeutic Agent for Cancer
US20090239859A1 (en) 2008-02-29 2009-09-24 Chua Peter C Protein kinase modulators
US7595320B2 (en) 2005-03-04 2009-09-29 Aventis Pharma S.A. Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, process for preparing them, compositions containing them and use thereof
US7595330B2 (en) 2005-09-06 2009-09-29 Smithkline Beecham Corporation Benzimidazole thiophene compounds
WO2009120094A2 (en) 2008-03-27 2009-10-01 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
US20090247554A1 (en) 2006-03-30 2009-10-01 Takeda San Diego, Inc. Kinase inhibitors
US20090247567A1 (en) 2008-03-31 2009-10-01 Genentech, Inc. Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use
US20090247565A1 (en) 2005-10-21 2009-10-01 Jongwon Lim Tyrosine Kinase Inhibitors
US20090247538A1 (en) 2004-10-25 2009-10-01 Astex Therapeutics Limited Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors
US7598245B2 (en) 2003-08-06 2009-10-06 Vertex Pharmaceuticals Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
US7601724B2 (en) 2002-09-04 2009-10-13 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7601718B2 (en) 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
WO2009126635A1 (en) 2008-04-09 2009-10-15 Abbott Laboratories 2-amino-benzothiazole derivates useful as inhibitors of rock kinases
US20090258852A1 (en) 2005-07-08 2009-10-15 Arrington Kenneth L Inhibitors of Checkpoint Kinases
US7605160B2 (en) 2006-08-09 2009-10-20 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7605155B2 (en) 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
WO2009129211A1 (en) 2008-04-16 2009-10-22 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatidylinositol 3-kinase
US20090263397A1 (en) 2007-07-06 2009-10-22 Buck Elizabeth A Combination anti-cancer therapy
US20090263398A1 (en) 2006-07-14 2009-10-22 Astex Therapeutics Limited Pharmaceutical combinations
WO2009129259A2 (en) 2008-04-16 2009-10-22 Takeda Pharmaceutical Company Limited Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor
US7608622B2 (en) 2004-09-24 2009-10-27 Janssen Pharmaceutica Nv Imidazo[4,5-b]pyrazinone inhibitors of protein kinases
US20090270430A1 (en) 2005-10-07 2009-10-29 Exelixix, Inc. Pyridopyrimidinone Inhibitors of Pl3Kalpha
US20090270445A1 (en) 2006-01-18 2009-10-29 Amgen Inc. Thiazole compounds and methods of use
US20090270621A1 (en) 2003-08-14 2009-10-29 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors

Patent Citations (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3969287A (en) 1972-12-08 1976-07-13 Boehringer Mannheim Gmbh Carrier-bound protein prepared by reacting the protein with an acylating or alkylating compound having a carrier-bonding group and reacting the product with a carrier
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
US4247642A (en) 1977-02-17 1981-01-27 Sumitomo Chemical Company, Limited Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4301144A (en) 1979-07-11 1981-11-17 Ajinomoto Company, Incorporated Blood substitute containing modified hemoglobin
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4670417A (en) 1985-06-19 1987-06-02 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
WO1990005719A1 (en) 1988-11-23 1990-05-31 British Bio-Technology Limited Hydroxamic acid based collagenase inhibitors
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1993021259A1 (en) 1992-04-14 1993-10-28 Cornell Research Foundation Inc. Dendritic based macromolecules and method of production
US5646176A (en) 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
EP0606046A1 (en) 1993-01-06 1994-07-13 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids
JPH08176070A (en) 1994-12-19 1996-07-09 Mitsubishi Chem Corp Didepside derivative and pi3 kinase inhibitor
JPH08175990A (en) 1994-12-19 1996-07-09 Mitsubishi Chem Corp Pi3 kinase-inhibiting agent and its production
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
WO1996027583A1 (en) 1995-03-08 1996-09-12 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
WO1996033172A1 (en) 1995-04-20 1996-10-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
US5861510A (en) 1995-04-20 1999-01-19 Pfizer Inc Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
WO1997015658A1 (en) 1995-10-26 1997-05-01 Ludwig Institute For Cancer Research Wortmannin phosphoinositide 3-kinase interaction site
EP0780386A1 (en) 1995-12-20 1997-06-25 F. Hoffmann-La Roche Ag Matrix metalloprotease inhibitors
WO1998003516A1 (en) 1996-07-18 1998-01-29 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
WO1998007697A1 (en) 1996-08-23 1998-02-26 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
WO1998030566A1 (en) 1997-01-06 1998-07-16 Pfizer Inc. Cyclic sulfone derivatives
WO1998033768A1 (en) 1997-02-03 1998-08-06 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
WO1998034915A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
WO1998034918A1 (en) 1997-02-11 1998-08-13 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
WO1999002514A2 (en) 1997-07-08 1999-01-21 Bristol-Myers Squibb Company Epothilone derivatives
WO1999029667A1 (en) 1997-12-05 1999-06-17 Pfizer Limited Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors
EP0931788A2 (en) 1998-01-27 1999-07-28 Pfizer Limited Metalloprotease inhibitors
WO1999052889A1 (en) 1998-04-10 1999-10-21 Pfizer Products Inc. (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
WO1999052910A1 (en) 1998-04-10 1999-10-21 Pfizer Products Inc. Bicyclic hydroxamic acid derivatives
US6262094B1 (en) 1999-02-22 2001-07-17 Bristol-Myers Squibb Company C-21 modified epothilones
JP2001247477A (en) 2000-03-03 2001-09-11 Teikoku Hormone Mfg Co Ltd Antitumor medicine
WO2001081346A2 (en) 2000-04-25 2001-11-01 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
US6800620B2 (en) 2000-04-25 2004-10-05 Icos Inhibitors of human phosphatidylinositol 3-kinase delta
US6770641B2 (en) 2000-04-27 2004-08-03 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US6653320B2 (en) 2000-04-27 2003-11-25 Yamanouchi Pharmaceutical Co. Ltd. Imidazopyridine derivatives
US6838457B2 (en) 2000-04-27 2005-01-04 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US7037915B2 (en) 2000-04-27 2006-05-02 Astellas Pharma Inc. Fused heteroaryl derivatives
US6608056B1 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd Fused heteroaryl derivatives
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US7173029B2 (en) 2000-04-27 2007-02-06 Astellas Pharma Inc. Fused heteroaryl derivatives
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
US20040053946A1 (en) 2001-01-16 2004-03-18 Lackey Karen Elizabeth Cancer treatment method
EP1417976A1 (en) 2001-07-26 2004-05-12 Santen Pharmaceutical Co., Ltd. Remedy for glaucoma comprising as the active ingredient compound having pi3 kinase inhibitory effect
US6703414B2 (en) 2001-09-14 2004-03-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Device and method for treating restenosis
WO2003034997A2 (en) 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US20030158212A1 (en) 2001-10-24 2003-08-21 Teri Melese Modulators of phosphoinositide 3-kinase
US20030149074A1 (en) 2001-10-24 2003-08-07 Teri Melese Modulators of phosphoinositide 3-kinase
WO2003035618A2 (en) 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
WO2003037886A2 (en) 2001-10-30 2003-05-08 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
WO2004007491A1 (en) 2002-07-10 2004-01-22 Applied Research Systems Ars Holding N.V. Azolidinone-vinyl fused-benzene derivatives
WO2004006916A1 (en) 2002-07-10 2004-01-22 Applied Research Systems Ars Holding Nv Use of compounds for increasing spermatozoa motility
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
US7601724B2 (en) 2002-09-04 2009-10-13 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7605155B2 (en) 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US20040092561A1 (en) 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
US7601718B2 (en) 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US20060270673A1 (en) 2003-04-24 2006-11-30 Merck & Co., Inc. Inhibitors of akt activity
US7598245B2 (en) 2003-08-06 2009-10-06 Vertex Pharmaceuticals Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
US20090270621A1 (en) 2003-08-14 2009-10-29 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US20060115824A1 (en) * 2004-04-15 2006-06-01 Institute For Environmental Health, Inc. Trend analysis and statistical process control using multitargeted screening assays
US20090258359A1 (en) * 2004-08-06 2009-10-15 Institute For Environmental Health Modular compositing-multiple lot screening protocols for detection of pathogens, microbial contaminants and/or constituents
US7534584B2 (en) * 2004-08-06 2009-05-19 Institute For Environmental Health, Inc. Modular compositing-multiple lot screening protocols for detection of pathogens, microbial contaminants and/or constituents
US20090238828A1 (en) 2004-08-14 2009-09-24 Boehringer Ingelheim International Gmbh Combinations for the Treatment of Diseases involving Cell Proliferation
US7608622B2 (en) 2004-09-24 2009-10-27 Janssen Pharmaceutica Nv Imidazo[4,5-b]pyrazinone inhibitors of protein kinases
WO2006046035A1 (en) 2004-10-25 2006-05-04 Piramed Limited Pharmaceutical compounds
US20090247538A1 (en) 2004-10-25 2009-10-01 Astex Therapeutics Limited Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors
WO2006046031A1 (en) 2004-10-25 2006-05-04 Piramed Limited Pharmaceutical compounds
WO2006046040A1 (en) 2004-10-25 2006-05-04 Piramed Limited Pharmaceutical compounds
US20080207611A1 (en) 2004-10-25 2008-08-28 Plramed Limited Pharmaceutical compounds
US7595320B2 (en) 2005-03-04 2009-09-29 Aventis Pharma S.A. Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, process for preparing them, compositions containing them and use thereof
US20090258852A1 (en) 2005-07-08 2009-10-15 Arrington Kenneth L Inhibitors of Checkpoint Kinases
US7589101B2 (en) 2005-08-16 2009-09-15 Irm Llc Compounds and compositions as protein kinase inhibitors
US7595330B2 (en) 2005-09-06 2009-09-29 Smithkline Beecham Corporation Benzimidazole thiophene compounds
US20090270430A1 (en) 2005-10-07 2009-10-29 Exelixix, Inc. Pyridopyrimidinone Inhibitors of Pl3Kalpha
WO2007042810A1 (en) 2005-10-11 2007-04-19 Ludwig Institute For Cancer Research Pyrimidine derivatives for the treatment of cancer
WO2007042806A1 (en) 2005-10-11 2007-04-19 Ludwig Institute For Cancer Research Pyrimidine derivatives for the treatment of cancer
US20090247565A1 (en) 2005-10-21 2009-10-01 Jongwon Lim Tyrosine Kinase Inhibitors
US20090270445A1 (en) 2006-01-18 2009-10-29 Amgen Inc. Thiazole compounds and methods of use
US20090233950A1 (en) 2006-03-02 2009-09-17 Frederic Henri Jung Quinazoline derivatives
US20090247554A1 (en) 2006-03-30 2009-10-01 Takeda San Diego, Inc. Kinase inhibitors
US20080076768A1 (en) 2006-04-26 2008-03-27 Piramed Limited Pharmaceutical compounds
US20080039459A1 (en) 2006-04-26 2008-02-14 Plramed Limited Phosphoinositide 3-kinase inhibitor compounds and methods of use
US20090239936A1 (en) 2006-05-15 2009-09-24 Yoshikazu Sugimoto Prophylactic and Therapeutic Agent for Cancer
US20090234132A1 (en) 2006-05-23 2009-09-17 Novartis Ag 5-phenyl-thiazol-2-yl-urea derivatives and use as pi3 kinase inhibitors
US20090263398A1 (en) 2006-07-14 2009-10-22 Astex Therapeutics Limited Pharmaceutical combinations
US7605160B2 (en) 2006-08-09 2009-10-20 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US20090233926A1 (en) 2006-09-14 2009-09-17 Astrazeneca 2-benzimidazolyl-6-morpholino-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008070740A1 (en) 2006-12-07 2008-06-12 F.Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
WO2008073785A2 (en) 2006-12-07 2008-06-19 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and methods of use
US7592342B2 (en) 2007-05-10 2009-09-22 Smithkline Beecham Corporation Quinoxaline derivatives as PI3 kinase inhibitors
US20090263397A1 (en) 2007-07-06 2009-10-22 Buck Elizabeth A Combination anti-cancer therapy
WO2009105712A1 (en) 2008-02-22 2009-08-27 Irm Llc Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
US20090239859A1 (en) 2008-02-29 2009-09-24 Chua Peter C Protein kinase modulators
WO2009111547A1 (en) 2008-03-04 2009-09-11 Wyeth 7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
WO2009109867A2 (en) 2008-03-04 2009-09-11 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
WO2009111531A1 (en) 2008-03-06 2009-09-11 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2009112565A1 (en) 2008-03-13 2009-09-17 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-indazoles
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
WO2009117482A1 (en) 2008-03-19 2009-09-24 Osi Pharmaceuticals, Inc Mtor inhibitor salt forms
US20090239847A1 (en) 2008-03-19 2009-09-24 Ian Bruce Organic compounds
WO2009117097A1 (en) 2008-03-19 2009-09-24 Chembridge Corporation Novel tyrosine kinase inhibitors
WO2009120094A2 (en) 2008-03-27 2009-10-01 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
US20090247567A1 (en) 2008-03-31 2009-10-01 Genentech, Inc. Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use
WO2009126635A1 (en) 2008-04-09 2009-10-15 Abbott Laboratories 2-amino-benzothiazole derivates useful as inhibitors of rock kinases
WO2009129211A1 (en) 2008-04-16 2009-10-22 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatidylinositol 3-kinase
WO2009129259A2 (en) 2008-04-16 2009-10-22 Takeda Pharmaceutical Company Limited Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor

Non-Patent Citations (91)

* Cited by examiner, † Cited by third party
Title
"Basic and Clinical Pharmacology", 2003, MCGRAW HILL
"Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS
"Goodman and Gilman's The Pharmacological Basis of Therapeutics", 1996, pages: 11 - 16
"Handbook of Clinical Drug Data", 2002, MCGRAW-HILL
"Principles of Drug Action", 1990, CHURCHILL LIVINGSTON
"Remingtons Pharmaceutical Sciences", 2000, LIPPINCOTT WILLIAMS & WILKINS.
"The Pharmacological Basis of Therapeutics", 2001, MCGRAW HILL
ABID ET AL., ARTERIOSCLER. THROMB. VASE. BIOL., vol. 24, 2004, pages 294 - 300
AOUDJIT ET AL., J. IMMUNOL., vol. 161, 1998, pages 2333 - 2338
B. MARKMAN, ANNALS OF ONCOLOGY ADVANCE ACCESS, August 2009 (2009-08-01)
BACKER JM., BIOCHEM J, vol. 410, 2008, pages 1 - 17
BENNETT ET AL., J. PHARMACOL. EXP. THER., vol. 280, 1997, pages 988 - 1000
BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1784, 2008, pages 159 - 185
BLOEMEN ET AL., AM. J. RESPIR. CRIT. CARE MED., vol. 153, 1996, pages 521 - 529
BLUME- JENSEN P ET AL., NATURE, vol. 411, no. 6835, 2001, pages 355 - 365
BOWES ET AL., EXP. NEUROL., vol. 119, 1993, pages 215 - 219
BURGERING ET AL., NATURE, vol. 376, 1995, pages 599 - 602
CARNERO A, CURR CANCER DRUG TARGETS, vol. 8, 2008, pages 187 - 98
CHIOSIS ET AL., BIOORGANIC & MED. CHEM. LETT., vol. 11, 2001, pages 909 - 913
CHOPP ET AL., STROKE, vol. 25, 1994, pages 869 - 875
CLARK ET AL., NEUROSURG., vol. 75, 1991, pages 623 - 627
COSIMI ET AL., J. IMMUNOL., vol. 144, 1990, pages 4604 - 4612
COUSSENS; WERB, NATURE, vol. 420, 2002, pages 860 - 867
DEMEESTER ET AL., TRANSPLANTATION, vol. 62, 1996, pages 1477 - 1485
ENGELMAN JA, NAT REV GENET, vol. 7, 2006, pages 606 - 19
EXPERT OPIN. INVESTIG. DRUGS, vol. 18, no. 9, 2009, pages 1265 - 12 77
FISHMAN ET AL.: "Medicine", 1985, J.B. LIPPINCOTT CO.
FRASER ET AL., SCIENCE, vol. 251, 1991, pages 313 - 16
FRUMAN ET AL., ANN REV BIOCHEM, vol. 67, 1998, pages 481 - 507
GORCZYNSKI; WOJCIK, J. IMMUNOL., vol. 152, 1994, pages 2011 - 2019
GROSS ET AL., SCIENCE, vol. 218, 1998, pages 703 - 706
GUTE ET AL., MOL. CELL BIOCHEM., vol. 179, 1998, pages 169 - 187
HALLAHAN ET AL., PROC. NATL. ACAD. SCI (USA), vol. 94, 1997, pages 6432 - 6437
HALLORAN ET AL., ARTHRITIS RHEUM., vol. 39, 1996, pages 810 - 819
HARARI ET AL., ONCOGENE, vol. 19, 2000, pages 6102 - 6114
HARNING ET AL., TRANSPLANTATION, vol. 52, 1991, pages 842 - 845
HARTMAN ET AL., CARDIOVASC. RES., vol. 30, 1995, pages 47 - 54
HASAGAWA ET AL., INT. IMMUNOL., vol. 6, 1994, pages 831 - 838
HE ET AL., OPTHALMOL. VIS. SCI., vol. 35, 1994, pages 3218 - 3225
HERROLD ET AL., CELL IMMUNOL., vol. 157, 1994, pages 489 - 500
HIGUCHI ET AL.: "Prodrugs as Novel Delivery Systems", ASCD SYMPOSIUM SERIES, vol. 14
HORGAN ET AL., AM. J. PHYSIOL., vol. 261, 1991, pages H1578 - H1584
ISOBE ET AL., SCIENCE, vol. 255, 1992, pages 1125 - 1127
KAKIMOTO ET AL., CELL. IMMUNOL., vol. 142, 1992, pages 326 - 337
KAUFFMANN-ZEH ET AL., NATURE, vol. 385, 1997, pages 544 - 548
KAWASAKI ET AL., J. IMMUNOL., vol. 150, 1993, pages 1074 - 1083
KNOERZER ET AL., TOXICOL. PATHOL., vol. 25, 1997, pages 13 - 19
LEMMON ET AL., TRENDS CELL BIOL, vol. 7, 1997, pages 237 - 42
MA ET AL., ONCOGENE, vol. 19, 2000, pages 2739 - 2744
MARTINDALE: "The Extra Pharmacopoeia", 1999, THE PHARMACEUTICAL PRESS
MATTER A., DRUG DISC TECHNOL, vol. 6, 2001, pages 1005 - 1024
MULLIGAN ET AL., J. IMMUNOL., vol. 154, 1995, pages 1350 - 1363
MURPHY ET AL.: "Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery", 1997, PENGUIN BOOKS U.S.A., INC.
NAGASE ET AL., AM. J. RESPIR. CRIT. CARE MED., vol. 154, 1996, pages 504 - 510
NAKAO ET AL., MUSCLE NERVE, vol. 18, 1995, pages 93 - 102
NATHAN T., MOL CANCER THER., vol. 8, no. 1, January 2009 (2009-01-01)
NICHOLSON; ANDERSON, CELLULAR SIGNALLING, vol. H, 2002, pages 381 - 395
OPPENHEIMER-MARKS ET AL., J. CLIN. INVEST., vol. 101, 1998, pages 1261 - 1272
OSHIRO ET AL., STROKE, vol. 28, 1997, pages 2031 - 2038
PAGES ET AL., NATURE, vol. 369, 1994, pages 327 - 29
PANAYOTOU ET AL., TRENDS CELL BIOL, vol. 2, 1992, pages 358 - 60
PANES ET AL., GASTROENTEROLOGY, vol. 108, 1995, pages 1761 - 1769
PARKER ET AL., CURRENT BIOLOGY, vol. 5, 1995, pages 577 - 99
PHILLIPS ET AL., CANCER, vol. 83, 1998, pages 41
PHILP ET AL., CANCER RESEARCH, vol. 61, 2001, pages 7426 - 7429
PIXU LIU, NATURE REVIEWS DRUG DISCOVERY, vol. 8, 2009, pages 627 - 644
RAMEH ET AL., J. BIOL CHEM, vol. 274, 1999, pages 8347 - 8350
REMINGTON'S PHARMACEUTICAL SCIENCES, pages 1435 - 1712
ROMINA MARONE, BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1784, 2008, pages 159 - 185
RUDD, IMMUNITY, vol. 4, 1996, pages 527 - 34
SAMUELS ET AL., SCIENCE, vol. 304, 2004, pages 554
SAWYER, EXPERT OPINION INVESTIG. DRUGS, vol. JJ., 2004, pages 1 - 19
SCHIMMER ET AL., J. IMMUNOL., vol. 160, 1998, pages 1466 - 1477
SHAYESTEH ET AL., NATURE GENETICS., vol. 21, 1999, pages 99 - 102
SIMPSON; PARSONS, EXP. CELL RES., vol. 264, 2001, pages 29 - 41
STERNMARK ET AL., J CELL SCI, vol. 112, 1999, pages 4175 - 83
T. W. GREENE: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY & SONS
TALENTO ET AL., TRANSPLANTATION, vol. 55, 1993, pages 418 - 422
TAMIYA ET AL., IMMUNOPHARMACOLOGY, vol. 29, 1995, pages 53 - 63
TANAKA ET AL., J. IMMUNOL., vol. 151, 1993, pages 5088 - 5095
VANHAESEBROECK B, TRENDS BIOCHEM SCI, vol. 30, 2005, pages 194 - 204
VARA ET AL., CANCER TREATMENT REVIEWS, vol. 30, 2004, pages 193 - 204
VIVANCO ET AL., NATURE REV. CANCER, vol. 2, 2002, pages 489
VIVANCO; SAWYERS, NATURE REVIEWS CANCER, vol. 2, 2002, pages 489 - 501
VLAHOS ET AL., J. BIOL. CHEM., vol. 269, no. 7, 1994, pages 5241 - 5248
WALKER ET AL., MOL. CELL, vol. 6, 2000, pages 909 - 919
WEGNER ET AL., LUNG, vol. 170, 1992, pages 267 - 279
WEGNER ET AL., SCIENCE, vol. 247, 1990, pages 456 - 459
WHITMAN ET AL., NATURE, vol. 332, 1988, pages 664
YAO ET AL., SCIENCE, vol. 267, 1995, pages 2003 - 05
ZENG ET AL., TRANSPLANTATION, vol. 58, 1994, pages 681 - 689

Similar Documents

Publication Publication Date Title
Bruins Slot et al. Evaluating the performance of gluten ELISA test kits: The numbers do not tell the tale
Tittlemier et al. Sampling of cereals and cereal-based foods for the determination of ochratoxin A: an overview
EP1869961A3 (en) Automated seed sampler and methods of sampling, testing and bulking seeds
Schuller et al. A review of sampling plans and collaboratively studied methods of analysis for aflatoxins
Du et al. Combination of stable isotopes and multi-elements analysis with chemometric for determining the geographical origins of Rhizoma Coptidis
US20120090410A1 (en) Method for aflatoxin screening of products
Maestroni et al. Sampling strategies to control mycotoxins
WO2011049625A1 (en) Method for aflatoxin screening of products
WO2002103329A3 (en) Apparatus and method for determining the dispersibility of a product in particulate form
CN109490491A (en) A kind of food safety integrated analysis device
Sfeir et al. An evaluation of municipal solid waste composition bias sources
CN202028553U (en) Near-infrared high-flux nondestructive selection table device
Stroka et al. Novel sampling methods for the analysis of mycotoxins and the combination with spectroscopic methods for the rapid evaluation of deoxynivalenol contamination
Pacheco et al. Brazil nut sorting for aflatoxin prevention: a comparison between automatic and manual shelling methods
CN105807017A (en) Method for discriminating ham grades by using electronic nose
CN105994701A (en) Inspection and evaluation method for export gunpowder tea or mee tea
CN105675701A (en) GC-Q-TOF/MS detection technology of 708 pesticide residues in legume vegetables
CN105651917A (en) Detection technology for 708 kinds of pesticide residues GC-Q-TOF/MS in aquatic vegetables
US6888085B2 (en) Method and system for detection of contaminants in mail
Coker Design of sampling plans for determination of mycotoxins in foods and feeds
US9329162B2 (en) Auto micronaire
Daun et al. How green is green? Sampling and perception in assessing green seeds and chlorophyll in canola
Falconer et al. Automated color sorting of hand-harvested Chardonnay
Gu et al. Preparation and Certification of High‐Grade Gold Ore Reference Materials (GAu 19‐22)
Park et al. Performance of three pneumatic probe samplers and four analytical methods used to estimate aflatoxins in bulk cottonseed

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10825332

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 10825332

Country of ref document: EP

Kind code of ref document: A1